The GPRC5D-directed Therapies Market is emerging as a transformative area in oncology drug discovery, particularly for patients with relapsed or refractory multiple myeloma. GPRC5D (G protein-coupled receptor class C group 5 member D) has become a key focus in recent years due to its selective expression on malignant plasma cells and limited presence in normal tissues, making it a highly...